Table 4.

Table summarizing the association of baseline factors with OS in patients treated with platinum-based chemotherapy in the post-olaparib setting

UnivariateMultivariate
VariablesHRPHRP
Age (y)0.981 (0.948–1.015)0.267--
Grade (3 vs. 2)1.066 (0.325–3.493)0.916--
Stage at diagnosis (III or IV vs. I or II)1.072 (0.442–2.599)0.877--
Serous histology0.834 (0.293–2.380)0.735--
Optimally debulked (<1 cm)0.598 (0.291–1.229)0.162--
BRCA2 vs. BRCA10.970 (0.461–2.042)0.936--
Previous breast cancer0.661 (0.341–1.281)0.220--
Residual disease after first-line treatment1.665 (0.773–3.588)0.193--
Olaparib RECIST and/or GCIG response0.0310.056
 SD vs. PD0.299 (0.103–0.868)0.0260.301 (0.104–0.875)0.027
 PR/CR vs. PD0.257 (0.093–0.709)0.0090.298 (0.106–0.838)0.022
Last pre-PARPi platinum sensitivity0.332
 Partial sensitive vs. resistant0.902 (0.448–1.815)0.773--
 Sensitive vs. resistant0.522 (0.214–1.276)0.154
PTP interval (mo)0.960 (0.928–0.993)0.0180.962 (0.928–0.997)0.036